The present disclosure relates to a composition for increasing the expression of a growth factor gene, which contains core-shell structured microparticles as an active ingredient. When administered in vivo along with a growth factor gene, the composition for increasing the expression of a growth factor gene of the present disclosure can increase the expression of the co-administered gene by at least 30%. Especially, when administered along with at least one gene selected from a human hepatocyte growth factor (HGF) gene, an isoform gene of the human hepatocyte growth factor and a variant gene thereof, or at least one gene selected from a human insulin-like growth factor 1 (IGF1) gene, an isoform gene of the human insulin-like growth factor 1 and a variant gene thereof, which are appropriate for the present disclosure, the composition can increase the expression of the gene by at least 30%. When administered along with a gene therapeutic agent, the composition can achieve a therapeutic effect even with a very small amount of a gene, and thus is useful.

The present disclosure relates to a composition for increasing the expression of a growth factor gene, which contains core-shell structured microparticles as an active ingredient. When administered in vivo along with a growth factor gene, the composition for increasing the expression of a growth factor gene of the present disclosure can increase the expression of the co-administered gene by at least 30%. Especially, when administered along with at least one gene selected from a human hepatocyte growth factor (HGF) gene, an isoform gene of the human hepatocyte growth factor and a variant gene thereof, or at least one gene selected from a human insulin-like growth factor 1 (IGF1) gene, an isoform gene of the human insulin-like growth factor 1 and a variant gene thereof, which are appropriate for the present disclosure, the composition can increase the expression of the gene by at least 30%. When administered along with a gene therapeutic agent, the composition can achieve a therapeutic effect even with a very small amount of a gene, and thus is useful.

The method and preparation for the delivery of selective small molecule phytochemical based and pharmacologically active media through a cell membrane to enhance food groups for health protection and benefits is a method of selectively delivering a pharmacologically active small molecule phytochemical to specifically targeted cells within a body. The method comprises attaching the pharmacologically active small molecule phytochemical to a nutrient. The nutrient is selected such that the nutrient is selectively brought into the targeted cells as part of the metabolic process. The selected nutrient brings the pharmacologically active small molecule phytochemical through a cell membrane with the selected nutrient. The methodologies/process described in this application are referred to as the Guru-Vishnu process.

The method and preparation for the delivery of selective small molecule phytochemical based and pharmacologically active media through a cell membrane to enhance food groups for health protection and benefits is a method of selectively delivering a pharmacologically active small molecule phytochemical to specifically targeted cells within a body. The method comprises attaching the pharmacologically active small molecule phytochemical to a nutrient. The nutrient is selected such that the nutrient is selectively brought into the targeted cells as part of the metabolic process. The selected nutrient brings the pharmacologically active small molecule phytochemical through a cell membrane with the selected nutrient. The methodologies/process described in this application are referred to as the Guru-Vishnu process.

An example embodiment may involve (i) receiving, by a server device, deoxyribonucleic acid (DNA) information associated with a user; (ii) parsing, by the server device, the DNA information to identify one or more single nucleotide polymorphisms (SNPs)(iii) determining, by the server device and based, on the identified SNPs, an endocannabinoid genotype of the user; (iv) determining, based on the endocannabinoid genotype of the user, a recommendation of one or more cannabinoid formulations; (v) transmitting, to a client device associated with the user, a web-based representation of a first graphical user interface; and (vi) receiving, from the client device, an indication to display a detailed representation of a particular cannabinoid formulation of the one or more cannabinoid formulations.

An example embodiment may involve (i) receiving, by a server device, deoxyribonucleic acid (DNA) information associated with a user; (ii) parsing, by the server device, the DNA information to identify one or more single nucleotide polymorphisms (SNPs)(iii) determining, by the server device and based, on the identified SNPs, an endocannabinoid genotype of the user; (iv) determining, based on the endocannabinoid genotype of the user, a recommendation of one or more cannabinoid formulations; (v) transmitting, to a client device associated with the user, a web-based representation of a first graphical user interface; and (vi) receiving, from the client device, an indication to display a detailed representation of a particular cannabinoid formulation of the one or more cannabinoid formulations.

Disclosed are methods, compounds, and compositions for treating infection by an Apicomplexan parasite that include administering a compound that selectively inactivates ornithine aminotransferase of the Apicomplexan parasite. Specifically, the methods, compounds, compounds may be utilized for treating infection by Toxoplasma gondii and toxoplasmosis and for treating infection by Plasmodium falciparum and malaria. The compounds disclosed herein are observed to selectively inactivate Toxoplasma gondii ornithine aminotransferase (TgOAT) relative to human OAT and relative to human -aminobutyric aminotransferase (GABA-AT).

Disclosed are methods, compounds, and compositions for treating infection by an Apicomplexan parasite that include administering a compound that selectively inactivates ornithine aminotransferase of the Apicomplexan parasite. Specifically, the methods, compounds, compounds may be utilized for treating infection by Toxoplasma gondii and toxoplasmosis and for treating infection by Plasmodium falciparum and malaria. The compounds disclosed herein are observed to selectively inactivate Toxoplasma gondii ornithine aminotransferase (TgOAT) relative to human OAT and relative to human -aminobutyric aminotransferase (GABA-AT).

The disclosure is directed to formulations comprising cannabinoids. More particularly, the cannabinoid formulations can be designed to align with an individual's genotype based on a defined list of polymorphisms.

The disclosure is directed to formulations comprising cannabinoids. More particularly, the cannabinoid formulations can be designed to align with an individual's genotype based on a defined list of polymorphisms.